Katy Rezvani

Katy Rezvani is a pioneer in developing CAR-engineered natural killer (NK) cells for cancer therapy. Her laboratory has advanced cord blood-derived CAR-NK cells as an off-the-shelf cellular therapy, demonstrating remarkable safety and efficacy in early clinical trials. Rezvani's work addresses key limitations of CAR-T cells, including the potential for allogeneic use without severe graft-versus-host disease.

Katy Rezvani是开发CAR工程化自然杀伤（NK）细胞用于癌症治疗的先驱。她的实验室推进了脐带血来源的CAR-NK细胞作为现成的细胞治疗，在早期临床试验中展示了显著的安全性和有效性。Rezvani的工作解决了CAR-T细胞的关键局限性，包括在不发生严重移植物抗宿主病的情况下进行异基因使用的潜力。